ABSTRACT

Introduction

Anti-tumor necrosis factor agents are key treatment options in moderate–severe psoriasis. The advent of multiple biosimilars of these drugs provides a major opportunity to address this particular factor by helping to reduce costs. Reduced cost can help improve undertreatment, which is one of the challenges in treating moderate-severe psoriasis. There is now a wealth of real-world evidence demonstrating that patients with psoriasis can be initiated on – or transitioned to – an anti-TNF biosimilar without detrimental effects on overall safety and efficacy. Furthermore, recent results suggest that patients can be switched between different biosimilar versions of the same anti-TNF agent without any compromise in outcomes.

Areas covered

In this review, we summarized the role of anti-TNFs in psoriasis, health economic aspects of anti-TNF biosimilars, and their real-world data in clinical practice and registries.

Expert opinion

The introduction and competition of anti-TNF biosimilars reduced the cost of biologics and accumulated real-world data support efficacy and safety of anti-TNF biosimilars for psoriasis treatment. Although IL-17 and IL-23 inhibitors show better efficacy in psoriasis patients, long-term efficacy and safety data of anti-TNF and cost-effectiveness of anti-TNF biosimilars may play an important role to increase patient access to biologics through greater adoption of biosimilars.

中文翻译：

---

银屑病中的抗肿瘤坏死因子药物：使用生物仿制药解决关键挑战。

摘要

介绍

抗肿瘤坏死因子药物是中重度银屑病的关键治疗选择。这些药物的多种生物仿制药的出现为通过帮助降低成本来解决这一特定因素提供了重要机会。降低成本有助于改善治疗不足，这是治疗中重度银屑病的挑战之一。现在有大量真实世界的证据表明银屑病患者可以开始或过渡到抗 TNF 生物仿制药，而不会对整体安全性和有效性产生不利影响。此外，最近的结果表明，患者可以在相同抗 TNF 药物的不同生物仿制药之间切换，而不会影响结果。

覆盖区域

在这篇综述中，我们总结了抗 TNF 在银屑病中的作用、抗 TNF 生物仿制药的健康经济方面及其在临床实践和注册中的真实数据。

专家意见

抗 TNF 生物仿制药的引入和竞争降低了生物制剂的成本，积累的真实世界数据支持抗 TNF 生物仿制药治疗银屑病的有效性和安全性。尽管 IL-17 和 IL-23 抑制剂在银屑病患者中显示出更好的疗效，但抗 TNF 的长期疗效和安全性数据以及抗 TNF 生物仿制药的成本效益可能在通过更多采用增加患者获得生物制剂方面发挥重要作用生物仿制药。